MA42458A - Systèmes améliorés d'administration de nanoparticules - Google Patents
Systèmes améliorés d'administration de nanoparticulesInfo
- Publication number
- MA42458A MA42458A MA042458A MA42458A MA42458A MA 42458 A MA42458 A MA 42458A MA 042458 A MA042458 A MA 042458A MA 42458 A MA42458 A MA 42458A MA 42458 A MA42458 A MA 42458A
- Authority
- MA
- Morocco
- Prior art keywords
- delivery systems
- nanoparticle delivery
- improved nanoparticle
- improved
- systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562192973P | 2015-07-15 | 2015-07-15 | |
US201562252396P | 2015-11-06 | 2015-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42458A true MA42458A (fr) | 2018-05-23 |
Family
ID=57757767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042458A MA42458A (fr) | 2015-07-15 | 2016-07-14 | Systèmes améliorés d'administration de nanoparticules |
Country Status (17)
Country | Link |
---|---|
US (3) | US10285951B2 (fr) |
EP (1) | EP3322404A4 (fr) |
JP (2) | JP2018521068A (fr) |
KR (1) | KR20180029242A (fr) |
CN (1) | CN107920985B (fr) |
AU (2) | AU2016294617B2 (fr) |
BR (1) | BR112018000217A2 (fr) |
CA (1) | CA2991062C (fr) |
CO (1) | CO2018000146A2 (fr) |
HK (1) | HK1251159A1 (fr) |
IL (1) | IL256797B (fr) |
MA (1) | MA42458A (fr) |
MX (1) | MX2018000611A (fr) |
RU (1) | RU2018105494A (fr) |
SG (1) | SG10201912394VA (fr) |
WO (1) | WO2017011685A1 (fr) |
ZA (1) | ZA201800130B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018370237A1 (en) * | 2017-11-20 | 2020-06-04 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
US20210023017A1 (en) * | 2018-03-16 | 2021-01-28 | University Of Massachusetts | Yeast cell wall particle encapsulation of biodegradable pro-payloads |
KR102088663B1 (ko) * | 2018-03-20 | 2020-03-13 | 한국세라믹기술원 | 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도 |
WO2020123481A1 (fr) * | 2018-12-10 | 2020-06-18 | Celator Pharmaceuticals Inc. | Formulations combinées de taxanes et d'inhibiteurs de mtor |
KR20220045203A (ko) * | 2019-08-13 | 2022-04-12 | 펩티노보 바이오파마, 인크. | 암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm |
MX2023011004A (es) | 2021-03-19 | 2024-01-08 | Trained Therapeutix Discovery Inc | Compuestos para regular la inmunidad entrenada y métodos para usarlos. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4778679B2 (ja) | 2001-10-03 | 2011-09-21 | セレーター ファーマシューティカルズ インコーポレイテッド | 併用薬剤を送達するための組成物 |
AU2002350207A1 (en) * | 2001-11-19 | 2003-06-10 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
KR20050109498A (ko) * | 2003-02-20 | 2005-11-21 | 유니버시티 오브 코네티컷 헬스 센터 | 암 또는 전염병 치료에서 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물을 사용하는 방법 |
JP2008506780A (ja) | 2004-07-19 | 2008-03-06 | セレーター ファーマスーティカルズ、インク. | 活性剤放出のための粒子状構築物 |
KR20080009196A (ko) * | 2005-04-12 | 2008-01-25 | 위스콘신 얼럼나이 리서어치 화운데이션 | 중합체 및 패신저 약물의 마이셀 조성물 |
US8486924B2 (en) * | 2007-11-28 | 2013-07-16 | Celator Pharmaceuticals, Inc. | Taxane delivery system |
MX2011010390A (es) * | 2009-03-30 | 2011-12-14 | Cerulean Pharma Inc | Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso. |
CN102713606A (zh) | 2009-11-13 | 2012-10-03 | 无限制药股份有限公司 | 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法 |
CN103079546A (zh) * | 2010-08-20 | 2013-05-01 | 天蓝制药公司 | 治疗性肽-聚合物缀合物、粒子、组合物以及相关方法 |
JP2013543008A (ja) | 2010-11-19 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | Braf阻害剤による治療方法 |
CA2834619A1 (fr) * | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Administration regulee d'immunosuppresseurs a partir de nanovecteurs synthetiques |
WO2012166923A2 (fr) * | 2011-05-31 | 2012-12-06 | Bind Biosciences | Nanoparticules polymères chargées de médicament et leurs procédés de fabrication et d'utilisation |
DE102011109374A1 (de) * | 2011-08-04 | 2013-02-07 | Bock 1 Gmbh & Co. Kg | Stuhl mit Wippmechanik |
WO2016004048A2 (fr) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Conjugués ciblés, particules et préparations associées |
-
2016
- 2016-07-14 RU RU2018105494A patent/RU2018105494A/ru not_active Application Discontinuation
- 2016-07-14 CA CA2991062A patent/CA2991062C/fr active Active
- 2016-07-14 AU AU2016294617A patent/AU2016294617B2/en active Active
- 2016-07-14 KR KR1020187004307A patent/KR20180029242A/ko not_active Application Discontinuation
- 2016-07-14 SG SG10201912394VA patent/SG10201912394VA/en unknown
- 2016-07-14 CN CN201680041368.XA patent/CN107920985B/zh active Active
- 2016-07-14 MX MX2018000611A patent/MX2018000611A/es unknown
- 2016-07-14 US US15/744,723 patent/US10285951B2/en active Active
- 2016-07-14 JP JP2018500438A patent/JP2018521068A/ja not_active Withdrawn
- 2016-07-14 WO PCT/US2016/042330 patent/WO2017011685A1/fr active Application Filing
- 2016-07-14 BR BR112018000217A patent/BR112018000217A2/pt not_active Application Discontinuation
- 2016-07-14 EP EP16825199.9A patent/EP3322404A4/fr not_active Withdrawn
- 2016-07-14 MA MA042458A patent/MA42458A/fr unknown
-
2018
- 2018-01-08 IL IL256797A patent/IL256797B/en active IP Right Grant
- 2018-01-08 ZA ZA2018/00130A patent/ZA201800130B/en unknown
- 2018-01-09 CO CONC2018/0000146A patent/CO2018000146A2/es unknown
- 2018-08-17 HK HK18110619.0A patent/HK1251159A1/zh unknown
-
2019
- 2019-03-15 US US16/355,594 patent/US20190209484A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/013,101 patent/US11413253B2/en active Active
-
2021
- 2021-11-08 JP JP2021181961A patent/JP2022033751A/ja active Pending
- 2021-12-16 AU AU2021286353A patent/AU2021286353A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2018105494A (ru) | 2019-08-15 |
BR112018000217A2 (pt) | 2018-09-04 |
AU2016294617A1 (en) | 2018-01-25 |
CA2991062C (fr) | 2023-06-20 |
SG10201912394VA (en) | 2020-02-27 |
US20210052508A1 (en) | 2021-02-25 |
US10285951B2 (en) | 2019-05-14 |
EP3322404A4 (fr) | 2019-03-20 |
JP2018521068A (ja) | 2018-08-02 |
IL256797B (en) | 2021-05-31 |
ZA201800130B (en) | 2018-12-19 |
US20190209484A1 (en) | 2019-07-11 |
CO2018000146A2 (es) | 2018-04-19 |
US11413253B2 (en) | 2022-08-16 |
AU2016294617B2 (en) | 2021-09-16 |
JP2022033751A (ja) | 2022-03-02 |
KR20180029242A (ko) | 2018-03-20 |
CN107920985A (zh) | 2018-04-17 |
RU2018105494A3 (fr) | 2019-12-17 |
EP3322404A1 (fr) | 2018-05-23 |
IL256797A (en) | 2018-06-28 |
CA2991062A1 (fr) | 2017-01-19 |
US20180207104A1 (en) | 2018-07-26 |
MX2018000611A (es) | 2018-09-06 |
WO2017011685A1 (fr) | 2017-01-19 |
HK1251159A1 (zh) | 2019-01-25 |
AU2021286353A1 (en) | 2022-01-20 |
CN107920985B (zh) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257215A1 (zh) | 操作多模式藥物輸送系統 | |
HK1257645A1 (zh) | 一種外用膜的送達系統 | |
HK1248570A1 (zh) | D2o穩定化的藥物製劑 | |
HK1245105A1 (zh) | 使用缺氧敏感性納米複合材料的葡萄糖響應性胰島素遞送系統 | |
ZA201807048B (en) | Medical delivery system | |
MA42458A (fr) | Systèmes améliorés d'administration de nanoparticules | |
BR112017023853A2 (pt) | composições de nanopartícula para terapia sustentada. | |
MA45472A (fr) | Systèmes d'administration pour la libération contrôlée de médicaments | |
IL243196A0 (en) | Provision and use of cas-crispr systems, vectors and preparations for targeting the liver and treatment | |
EP2950785A4 (fr) | Systèmes d'administration de médicament nanoparticulaires | |
ITUB20152886A1 (it) | Dispositivo di sicurezza per l'irrigazione nasale | |
DK3288955T3 (da) | Bortezomib-baseret afgivelsessystem | |
HUE057487T2 (hu) | Gyógyszeradagoló rendszer | |
IL274920B1 (en) | Maytansinoid-based drug delivery systems | |
IT201700026832A1 (it) | Sistema di erogazione | |
GB2551453B (en) | Nanocarrier delivery system for hydrophobic substances | |
IT201700043316A1 (it) | Drug delivery system | |
IL255229A (en) | Anionic nanoparticles for use in the delivery of anionic small molecule drugs | |
CL2017003077A1 (es) | Sistemas de administración oral para agentes bioactivos | |
IL275664A (en) | drug delivery system | |
EP3890784A4 (fr) | Système d'administration de nanoparticules | |
EP3434286A4 (fr) | Composition de nanoparticules d'administration de médicament | |
GB201514495D0 (en) | Self-emulsifying Nanosuspensions as Drug Delivery Systems | |
GB2559449B (en) | Hypoallergic drug delivery system | |
MA42522A (fr) | Système d'administration transdermique |